All In MedTech

FDA Clearance Tracker · P970043-S025

LADARVISION 4000 EXCIMER LASER SYSTEM AND THE LADAR 6000 EXCIMER LASER SYSTEM

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 5, 2006 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 5, 2006

Approved

Time to decision

154 days

Received Feb 1, 2006. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P970043-S025
Device name
LADARVISION 4000 EXCIMER LASER SYSTEM AND THE LADAR 6000 EXCIMER LASER SYSTEM
Applicant location
Fort Worth, TX
Received
Feb 1, 2006
Decided
Jul 5, 2006
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P970043

Device type

Device class
Class III
Specialty
Ophthalmology

Every decision under product code LZS

FDA's approval statement

As written in FDA's record.

APPROVAL FOR AN EXPANSION OF THE ALLOWABLE RANGE FOR THE PHYSICIAN ADJUSTMENT OF DEFOCUS OFFSET PARAMETER FOR THE WAVEFRONT-GUIDED MYOPIA AND MYOPIC ASTIGMATISM INDICATIONS FROM +=0.75 D TO UP TO 1.00 D INCREASE (MORE MYOPIC TREATMENT) AND UP TO 2.50 D DECREASE (LESS MYOPIC TREATMENT).

Source documents

Other decisions for Alcon Laboratories

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.